PIMA183460
Shigella dysenteriae 1 Monoclonal Antibody (35/383), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA183460-Each-of-1 | In Stock | ₹ 50,774.50 |
PIMA183460 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 50,774.50
GST (18%): ₹ 9,139.41
Total Price: ₹ 59,913.91
Antigen
Shigella dysenteriae 1
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 0.09% sodium azide; pH 7.2
Host Species
Mouse
Purification Method
Protein A
Regulatory Status
RUO
Target Species
Bacteria
Product Type
Antibody
Isotype
IgG3
Applications
ELISA, Immunocytochemistry
Clone
35/383
Conjugate
Unconjugated
Gene Alias
S. dysenteriae; shigella; shigellosis
Immunogen
Native S. dysenteriae, NCTC 4837 (ATCC 13313).
Quantity
200 μg
Primary or Secondary
Primary
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- Mouse anti Shigella dysenteriae antibody, clone 35/383 recogniszs serotype 1 Shigella dysenteriae, a gram-negative bacteria and causative agent of dysentery in humans
- Although pathogenic bacteria constitute only a small portion of bacterial species, infectious diseases caused by pathogenic bacteria affect millions of people worldwide
- Diarrheal diseases, many of which are bacterial, are the second leading cause of death worldwide, claiming an estimated 5 million people annually
- Furthermore, an estimated 3 million people die of tuberculosis annually, 500,000 people die of pertussis, and 25,000 die of typhoid
- The ability of bacteria to utilize various food sources is a major factor behind their pervasiveness
- Their vast numbers lead to rapid evolutionary changes resulting in emerging diseases as well as antibiotic-resistant strains of well known diseases
- Examples of these are multi-drug resistant tuberculosis and methicillin-resistant Staphylococcus aureus
- Research into the detection and treatment of these infectious disease agents will continue to expand in an effort to alleviate the effects of these diseases.